Table III.

 Hazard Ratios (95% Confidence Interval) for ARB vs ACE Inhibitor for Study Outcomes, Stratified by Subgroup

	Mortality	Stroke	CAD	Diabetes	CKD
All	0.95 (0.82–1.09)	1.09 (0.87–1.35)	1.01 (0.84–1.22)	1.28 (1.08–1.52)	1.10 (0.92–1.32)
Age 50–65	1.60 (0.71–3.60)	2.00 (0.71–5.62)	1.14 (0.56–2.35)	0.73 (0.38–1.40)	3.00 (0.85–10.63)
Age 65+	0.85 (0.70–1.02)	1.00 (0.75–1.34)	1.15 (0.87–1.52)	1.35 (1.03–1.77)	1.03 (0.81–1.32)
Male	1.02 (0.83–1.27)	1.13 (0.83–1.54)	1.19 (0.90–1.56)	1.39 (1.09–1.77)	1.19 (0.92–1.55)
Female	0.88 (0.63–1.21)	1.09 (0.61–1.95)	0.73 (0.46–1.15)	1.93 (1.22–3.07)	0.77 (0.53–1.13)

Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CKD, chronic kidney disease.